Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2005-000865-21-IT
EUCTR2005-000865-21-IT
Active, not recruiting
Not Applicable

A phase IV, open-label, randomized, multicenter trial assessing the efficacy of a treatment maintenance phase with unboosted vs boosted Reyataz after an induction phase with Reytaz and Ritonavir in treatment naive HIV patients

BRISTOL-M.SQUIBB0 sitesJanuary 30, 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHIV treatmentMedDRA version: 6.1Level: HLTClassification code 10038997
DrugsNORVIR 336 CPS 100 MG

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
HIV treatment
Sponsor
BRISTOL-M.SQUIBB
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 30, 2006
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
BRISTOL-M.SQUIBB

Eligibility Criteria

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A phase IV, open-label, randomized, multicenter trial assessing a reyataz-based substitution approach in the management of lipodystrophy syndrome.HIVMedDRA version: 6.1Level: PTClassification code 10049287
EUCTR2004-002740-10-ITBRISTOL-M.SQUIBB300
Active, not recruiting
Not Applicable
A phase IV, randomized, open-label, multi-center study in adults: Evaluation of long-term immunogenicity in subjects boosted with a new TBE vaccine for adults (free of protein-derived stabilizer) in study V48P2E1, 5 years after first booster immunization and Evaluation of booster kinetics in subjects boosted with a new TBE vaccine for adults (free of protein-derived stabilizer), 5 years after first booster immunization. - not availableTBE prophylaxis
EUCTR2005-004459-36-DEChiron Behring GmbH & Co KG190
Completed
Phase 4
Immunogenicity and safety of Rabies Vaccine, adimistered with two different simulated post exposure regimens
CTRI/2011/07/001857ovartis Healthcare Pvt Ltd250
Active, not recruiting
Phase 1
Study of management of pasireotide-induced hyperglycemia in adult patients with Cushing’s disease or acromegaly
EUCTR2012-002916-16-BEovartis Pharma Services AG132
Active, not recruiting
Phase 1
Study of management of pasireotide-induced hyperglycemia in adult patients with Cushing’s disease or acromegalyCushing's disease and acromegalyMedDRA version: 19.0Level: LLTClassification code 10011651Term: Cushing's diseaseSystem Organ Class: 100000004860MedDRA version: 19.0Level: LLTClassification code 10000600Term: Acromegaly and gigantismSystem Organ Class: 100000004860Therapeutic area: Diseases [C] - Hormonal diseases [C19]
EUCTR2012-002916-16-PLovartis Pharma Services AG133